An evaluation of topical mupirocin in moderately severe primary and secondary skin infections.
Five days' treatment with topical mupirocin, applied twice daily, in 36 patients with moderately severe primary and secondary skin infections, resulted in resolution/much improvement of skin lesions in 75.0% of patients and bacterial eradication in 83.9% of cases. Penicillin-resistant and penicillin-sensitive staphylococci were most commonly implicated. No adverse effects were reported in any of the patients treated. Physicians' assessment of cure/improvement was recorded in 91.7% of patients.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D005227:Fatty Acids / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016712:Mupirocin; D010403:Penicillin Resistance; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000302:isolation & purification
D005227:Fatty Acids; D016712:Mupirocin